NCT03807245 - Group B Streptococcus Vaccine in Healthy Females | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2019

Primary Completion Date

October 14, 2019

Study Completion Date

May 7, 2020

Conditions

Group B Strep Infection

Interventions

BIOLOGICAL

GBS-NN/NN2 with Alhydrogel® 25

GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

BIOLOGICAL

Placebo GBS-NN/NN2 with Alhydrogel® 25

GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

BIOLOGICAL

Placebo GBS-NN/NN2 with Alhydrogel® 50

GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

BIOLOGICAL

GBS-NN/NN2 with Alhydrogel® 50

GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart

Trial Locations (1)

Simbec Research Limited, Merthyr Tydfil